Disclosure NewswireTMiCrowdNewswire - Oct 5, 2016
ST. LOUIS — Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that Ronald Reagan UCLA Medical Center in Los Angeles has installed the latest Niobe® ES remote magnetic navigation system, an upgrade of an existing Niobe I system.
The upgrade reflects the hospital’s commitment to the Niobe platform for the optimal treatment of complex arrhythmias, especially ventricular tachycardia (VT). The latest Niobe technology was implemented for increased operational efficiency and improved patient outcomes within the UCLA Cardiac Arrhythmia Center, a leading tertiary-care center committed to the field of arrhythmias and cardiac electrophysiology and a division of UCLA Health and David Geffen School of Medicine at UCLA.
Led by Director Kalyanam Shivkumar, MD, PhD, the UCLA Cardiac Arrhythmia Center is dedicated to utilizing state-of-the-art medical technologies with compassionate care to address the needs of arrhythmia patients. The center first began utilizing the Niobe I system for complex arrhythmia procedures in February 2009 and quickly became an important advocate of the value of the Niobe system for treating VT. The UCLA team consists of Jason Bradfield MD, VT ablation program director, Eric Buch MD, lab director and AF ablation program director, Noel G. Boyle MD, Sam Fujimura MD, Marmar Vaseghi MD, Carlos Macias MD, Olu Ajijola MD, Yuliya Krokhaleva MD and Houman Khakpour MD.
Dr. Bradfield said, “The treatment of complex arrhythmias such as VT is extremely challenging due to the location and the nature of the diseased tissue. The Niobe system provides our team of physicians with unique capabilities for accessing the targeted areas within the ventricles with extremely high precision. Using the latest features available within the Niobe ES system, we look forward to addressing these life-threatening conditions with higher acute success, improved safety, and better long-term outcomes.”
Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis’ core Epoch® Solution includes the Niobe® magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management solutions, and the Vdrive® robotic navigation system and consumables.
The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Canada, China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator, V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter advancement system have received clearance in the United States, Canada, and the European Union. The V-CAS Deflect™ catheter advancement system has been CE Marked for sale in the European Union. For more information, please visit www.stereotaxis.com.
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness, or to obtain additional debt financing, in either case on acceptable terms, continued acceptance of the Company’s products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.
Company Contact: Martin C. Stammer Chief Financial Officer 314-678-6155 Investor Contact: Todd Kehrli / Jim Byers MKR Group, Inc. 323-468-2300 firstname.lastname@example.org